Log In
BCIQ
Print this Print this
 

dapagliflozin/metformin extended-release (Xigduo XR)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionExtended-release combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today